Subsequent data from the FORWARD database demonstrated that 5.9% of patients with RA treated with TNF inhibitors, non‐TNF inhibitors, bDMARDs (abatacept, rituximab, tocilizumab and anakinra) or csDMARDs (n = 11,623) experienced an SI during 27,552 patient-years of follow-up [89]. The gene discussed is TNF; the disease is rheumatoid arthritis.